BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA ...

Luotea PlcStock exchange release 26 February 2026 at 8:00 p.m. Luotea publishes comparative information for continuing operations for the years 2024 and 2025 On 7 August 2025, Luotea Plc published the ...

Detailed price information for Orezone Gold Corp (ORE-T) from The Globe and Mail including charting and trades.

Entities often provide certain information about their financial performance beyond typical PFRS totals, such as certain additional performance metrics to guide decision-making and communicate results ...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...

Solution Financial Inc. (TSX: SFI) (the “Company”) a leading provider of luxury and ultra luxury asset leasing in ...

Crown Point Energy Inc. is an international oil and gas exploration and development company headquartered in Buenos Aires, Argentina, incorporated in Canada, trading on the TSX Venture Exchange and ...

Zuari Agro Chemicals Ltd and four of its senior officials have settled adjudication proceedings with the market regulator Securities and Exchange Board of India (SEBI) by paying about ₹2.91 crore as ...

Yuanbao Inc. (“Yuanbao” or the “Company”) (NASDAQ: YB), a leading technology-driven online insurance distributor in China, today announced its unaudited financial results for the fourth quarter and ...

J.B. Maverick is an active trader, commodity futures broker, and stock market analyst 17+ years of experience, in addition to 10+ years of experience as a finance writer and book editor. David ...

Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fourth quarter and full year 2025 financial results and provided business ...

CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed ...